Sereboff v. Mid Atlantic Medical Services, Inc.

HARD ROCK HOTEL & CASINO ATLANTIC CITY'S ANNUAL PINKTOBER CAMPAIGN RAISES OVER $164,000 FOR AMERICAN CANCER SOCIETY

Retrieved on: 
Thursday, November 9, 2023
American Cancer Society, Hard Rock Live (Atlantic City), Research, Breast cancer, Breast Cancer Awareness Month, Sereboff v. Mid Atlantic Medical Services, Inc., American Cancer Society Cancer Action Network, Hard Rock Cafe, Hard Rock Live, Casino, Hard Rock Hotel & Casino Atlantic City

ATLANTIC CITY, N.J., Nov. 9, 2023 /PRNewswire/ -- Hard Rock Hotel & Casino Atlantic City raised over $164,000 through their annual Pinktober initiative, ranking the resort nationally as the No.1 fundraising team by the American Cancer Society. Pinktober is a part of the Hard Rock Heals Foundation, the charitable arm of Hard Rock International, with proceeds benefiting American Cancer Society to support breast cancer awareness and research. To date, Hard Rock International has raised more than $10 million since the inception of Pinktober 23 years ago including $1.2 million raised in 2022. The funds raised by Hard Rock Atlantic City will benefit the American Cancer Society's mission locally.

Key Points: 
  • ATLANTIC CITY, N.J., Nov. 9, 2023 /PRNewswire/ -- Hard Rock Hotel & Casino Atlantic City raised over $164,000 through their annual Pinktober initiative, ranking the resort nationally as the No.1 fundraising team by the American Cancer Society.
  • Pinktober is a part of the Hard Rock Heals Foundation, the charitable arm of Hard Rock International, with proceeds benefiting American Cancer Society to support breast cancer awareness and research.
  • The funds raised by Hard Rock Atlantic City will benefit the American Cancer Society's mission locally.
  • "Hard Rock Atlantic City is honored to raise awareness and funds through our Pinktober initiative to support our community and the American Cancer Society," said George Goldhoff, President of Hard Rock Hotel & Casino Atlantic City.

Novaliq Announces FDA Approval of VEVYE™ (Cyclosporine Ophthalmic Solution) 0.1% for the Treatment of the Signs and Symptoms of Dry Eye Disease

Retrieved on: 
Thursday, June 8, 2023
Biotechnology, FDA, Health, Pharmaceutical, Optical, DED, Dry eye syndrome, Therapy, Eastern Virginia Medical School, Telecanthus, Signs and symptoms, Visual impairment, Food, Multimedia, Inflammation, Doctor of Philosophy, US, Oil, Patient, Treatment, Water, Ophthalmology, Signs, Ciclosporin, FACS, Sereboff v. Mid Atlantic Medical Services, Inc., Regulation of food and dietary supplements by the U.S. Food and Drug Administration, MMSc, US FDA, Safety, Disease, Pharmaceutical industry, MD

VEVYE (development name CyclASol®) is the first and only cyclosporine solution indicated for the treatment of signs and symptoms of dry eye disease with efficacy demonstrated after 4 weeks of treatment.

Key Points: 
  • VEVYE (development name CyclASol®) is the first and only cyclosporine solution indicated for the treatment of signs and symptoms of dry eye disease with efficacy demonstrated after 4 weeks of treatment.
  • View the full release here: https://www.businesswire.com/news/home/20230608005090/en/
    Novaliq Announces FDA Approval of VEVYE™ (Cyclosporine Ophthalmic Solution) 0.1%, for the Treatment of the Signs and Symptoms of Dry Eye Disease (Photo: Business Wire)
    “We are proud that FDA approved VEVYE.
  • The safety and efficacy of VEVYE were assessed in a total of 1369 patients with dry eye disease, of which 738 received VEVYE.
  • We will continue to execute on our mission to transform ocular therapies by developing breakthrough novel EyeSol® therapies way beyond dry eye disease.”

CloudMD Expands Partnership with Benefits Alliance to Include Full Suite of Kii Services

Retrieved on: 
Wednesday, April 12, 2023
Partnership, Inter-State Bus Terminals, Sereboff v. Mid Atlantic Medical Services, Inc., Health, OTCQX, Health insurance, Financial adviser, Telehealth, Kii

The expanded partnership allows over 8,000 employee benefit plans across Canada to have access to Kii.

Key Points: 
  • The expanded partnership allows over 8,000 employee benefit plans across Canada to have access to Kii.
  • “This multi-product partnership with Benefits Alliance is an example of the transition we are making from a provider of standalone services to one focused on multi-product, whole person care.
  • The partnership’s expansion comes from a successful 3-year partnership,” said Karen Adams, CEO of CloudMD.
  • Benefits Alliance advisors manage over 8,000 employee benefits plans, with over $1.4 billion of group insurance premiums as well as of 1,500 group retirement plans that have over $3.5 billion in plan assets.

TearSolutions Expands and Establishes Advisory Boards and Strengthens Leadership Team

Retrieved on: 
Tuesday, March 7, 2023
Optometry and Vision Science, Employment Medical Advisory Service, Telecanthus, Dean, CMC, Internet, SAB, Drug development, MPH, DED, University of Pittsburgh School of Medicine, Tear Film and Ocular Surface Society, Cornea, Sereboff v. Mid Atlantic Medical Services, Inc., Strategic Advisory Group of Experts, III, Takeda, University of California, Berkeley, Central Waqf Council, Medical director, Doctor of Pharmacy, Dean (education), Physician, MAB, Herbert Wertheim School of Optometry and Vision Science, Wilfrid Sellars, Johnson & Johnson Vision, MS, University, Research, Doctor of Philosophy, U.S. FDA, FDA, Birmingham School, UCB, File, Pharmaceutical industry, Hospital, OD, Novartis, Optometry, MD, Ophthalmology

“We are honored and excited to have such an accomplished group of advisors working with us.

Key Points: 
  • “We are honored and excited to have such an accomplished group of advisors working with us.
  • We are confident in his leadership and are pleased to announce his promotion to Chief Development Officer.”
    The establishment of TearSolutions’ Strategic Advisory board was accomplished with the appointment of Dr. Amir Shojaei, PharmD, PhD.
  • His team brought Xiidra® (lifitegrast) from development through to U.S. FDA filing and approval.
  • Mr. Cook has been working with TearSolutions since 2020, following more than 30 years of experience developing eye care products.

AvalonBay Communities, Inc. Completes $350 Million Senior Notes Offering

Retrieved on: 
Wednesday, December 7, 2022
Other Construction & Property, Residential Building & Real Estate, Construction & Property, REIT, Security (finance), Note, Research Triangle, Sale, All rights reserved, AvalonBay Communities, Annual report, Pacific Northwest, COVID-19, Sereboff v. Mid Atlantic Medical Services, Inc., REIT, Acquisition, Bank

The effective interest rate of the Notes is 4.373%, including the impact of offering costs and prior interest rate hedges.

Key Points: 
  • The effective interest rate of the Notes is 4.373%, including the impact of offering costs and prior interest rate hedges.
  • Interest on the Notes will be paid semi-annually on February 15 and August 15, with the first payment to be made on August 15, 2023.
  • The Notes will mature on February 15, 2033 unless earlier redeemed.
  • Copyright 2022 AvalonBay Communities, Inc. All Rights Reserved
    View source version on businesswire.com: https://www.businesswire.com/news/home/20221207005608/en/

AvalonBay Communities Prices Public Offering of 2,000,000 Shares of Common Stock

Retrieved on: 
Thursday, April 7, 2022
Residential Building & Real Estate, Commercial Building & Real Estate, Construction & Property, REIT, Morgan Stanley, Company, Private Securities Litigation Reform Act, Sale, JPMorgan Chase, Chase Bank, Attention, NYSE, Ownership, Varick Street, SEC, Sereboff v. Mid Atlantic Medical Services, Inc., U.S. Securities and Exchange Commission, District, Prospectus, All rights reserved, LLC, New, Pacific Northwest, Review, Securities Exchange Act of 1934, J. P. Morgan, 2nd Floor (Nina song), Securities Act of 1933, AvalonBay Communities, Broadridge Financial Solutions, AVB, COVID-19, Research Triangle, Annual report, Acquisition, Security (finance)

AVALONBAY COMMUNITIES, INC. (NYSE: AVB) (the Company) announced today that it has priced an underwritten public offering of 2,000,000 shares of common stock, all of which are being offered in connection with the forward sale agreements described below, for expected gross proceeds of approximately $497.2 million.

Key Points: 
  • AVALONBAY COMMUNITIES, INC. (NYSE: AVB) (the Company) announced today that it has priced an underwritten public offering of 2,000,000 shares of common stock, all of which are being offered in connection with the forward sale agreements described below, for expected gross proceeds of approximately $497.2 million.
  • or their affiliates (the forward purchasers) with respect to 2,000,000 shares of its common stock.
  • In connection with the forward sale agreements, the forward purchasers or their affiliates are expected to borrow and sell to the underwriters an aggregate of 2,000,000 shares of the common stock that will be delivered in the offering.
  • The Company will not initially receive any proceeds from the sale of shares of its common stock by the forward purchasers or their affiliates in the offering.

AvalonBay Communities Announces Public Offering of 2,000,000 Shares of Common Stock

Retrieved on: 
Wednesday, April 6, 2022
Architecture, Residential Building & Real Estate, Commercial Building & Real Estate, Construction & Property, Building Systems, REIT, Morgan Stanley, Company, Private Securities Litigation Reform Act, Sale, JPMorgan Chase, Chase Bank, Attention, NYSE, Ownership, Varick Street, SEC, Sereboff v. Mid Atlantic Medical Services, Inc., U.S. Securities and Exchange Commission, District, Prospectus, All rights reserved, LLC, New, Pacific Northwest, Review, Securities Exchange Act of 1934, J. P. Morgan, 2nd Floor (Nina song), Securities Act of 1933, AvalonBay Communities, Broadridge Financial Solutions, AVB, COVID-19, Research Triangle, Acquisition, Security (finance)

AVALONBAY COMMUNITIES, INC. (NYSE: AVB) (the Company) announced today that it is commencing an underwritten public offering of 2,000,000 shares of common stock in connection with the forward sale agreements described below.

Key Points: 
  • AVALONBAY COMMUNITIES, INC. (NYSE: AVB) (the Company) announced today that it is commencing an underwritten public offering of 2,000,000 shares of common stock in connection with the forward sale agreements described below.
  • or their affiliates (the forward purchasers) with respect to 2,000,000 shares of its common stock.
  • In connection with the forward sale agreements, the forward purchasers or their affiliates are expected to borrow and sell to the underwriters an aggregate of 2,000,000 shares of the common stock that will be delivered in the offering.
  • The Company will not initially receive any proceeds from the sale of shares of its common stock by the forward purchasers or their affiliates in the offering.

AvalonBay Communities Announces $500 Million Commercial Paper Note Program

Retrieved on: 
Tuesday, March 15, 2022
Professional Services, Residential Building & Real Estate, Commercial Building & Real Estate, Finance, Construction & Property, REIT, Banking, Program, Result, Review, AvalonBay Communities, AVB, COVID-19, District, Compliance, Research Triangle, Securities Exchange Act of 1934, Security (finance), Pacific Northwest, Sereboff v. Mid Atlantic Medical Services, Inc., Act, Sale, Company, NYSE, Financial condition report, U.S. Securities and Exchange Commission, New, Securities Act of 1933, All rights reserved, Analysis, REIT, Ownership, Property management

AVALONBAY COMMUNITIES, INC. (NYSE: AVB) (the Company) announced today that it established a $500 million unsecured commercial paper note program in the United States.

Key Points: 
  • AVALONBAY COMMUNITIES, INC. (NYSE: AVB) (the Company) announced today that it established a $500 million unsecured commercial paper note program in the United States.
  • Under the terms of the program, the Company may issue, from time to time, unsecured commercial paper notes up to a maximum aggregate amount outstanding at any one time not to exceed $500 million.
  • The notes will be sold under customary terms in the United States commercial paper note market and will be at least equal in right of payment with all of the Companys other unsubordinated and unsecured indebtedness.
  • This press release shall not constitute an offer to sell or the solicitation of an offer to buy the notes under the Companys commercial paper program.

Anthem Blue Cross and Blue Shield Expands Virtual Primary Care, Providing Members Increased Access to Affordable, Convenient Care

Retrieved on: 
Tuesday, February 8, 2022
Technology, Insurance, Professional Services, Practice Management, Other Health, Internet, Managed Care, General Health, Pharmaceutical, Health, Blue, ASO, Blue Shield, Sereboff v. Mid Atlantic Medical Services, Inc., Allergy, Digital, Prescription, Blue Cross (animal charity), Health, Asthma, Anthem (company), Blue Cross, Blue Cross Blue Shield Association, Diabetes, Anthem, Health insurance, Medicine, Facebook

With virtual primary care, members will have access to a virtual care team that conducts an initial health check-in, creates a personalized care plan, and provides care services to help members improve their health and wellbeing all at no or low-cost.

Key Points: 
  • With virtual primary care, members will have access to a virtual care team that conducts an initial health check-in, creates a personalized care plan, and provides care services to help members improve their health and wellbeing all at no or low-cost.
  • And for members who already have a primary care provider, Anthems virtual primary care complements the healthcare services they receive from in-person care.
  • Anthem Blue Cross and Blue Shield is the trade name of Rocky Mountain Hospital and Medical Service, Inc., an independent licensee of the Blue Cross Blue Shield Association.
  • The Blue Cross and Blue Shield names and symbols are registered marks of the Blue Cross and Blue Shield Association.

AvalonBay Communities Announces Completion of Green Bond Offering

Retrieved on: 
Thursday, November 18, 2021
Professional Services, Residential Building & Real Estate, Commercial Building & Real Estate, Finance, Construction & Property, REIT, Private Securities Litigation Reform Act, Sereboff v. Mid Atlantic Medical Services, Inc., District, Security (finance), Pacific Northwest, Sale, Review, Securities Act of 1933, Annual report, Acquisition, Company, New, REIT, U.S. Securities and Exchange Commission, COVID-19, Securities Exchange Act of 1934, Ownership, Note, Research Triangle, Bank

The effective interest rate of the 2028 Notes is 2.037%, including the impact of offering costs.

Key Points: 
  • The effective interest rate of the 2028 Notes is 2.037%, including the impact of offering costs.
  • Interest on the 2028 Notes will be paid semi-annually on June 1 and December 1, with the first payment to be made on June 1, 2022.
  • The 2028 Notes will mature on December 1, 2028 unless earlier redeemed.
  • Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements.